Compare AU

Compare CURE vs. RINC

Compare shares and ETFs on the ASX that you can trade on Pearler.

Global X S&P Biotech ETF

ASX

Buy

Buy

Overview
Performance

Overview

When it comes to investing in the Australian stock market, shares and ETFs are a popular choice. Two options in the ASX are CURE and RINC. In this comparison, we'll delve into these options across various dimensions to help you make an informed investment decision.

Community Stats

CURE

RINC

Popularity

Low

Low

Pearlers invested

83

1

Median incremental investment

$619.50

$1,094.28

Median investment frequency

Monthly

Monthly

Median total investment

$1,437.24

$172.33

Average age group

> 35

26 - 35


Key Summary

CURE

RINC

Strategy

CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.

RINC.AX was created on 2018-02-13 by BetaShares. The fund's investment portfolio concentrates primarily on total market equity. The ETF currently has 54.53m in AUM and 41 holdings. The Fund aims to provide a pre-tax income yield above the S&P/ASX 200 Index and to grow this income above the rate of inflation.

Top 3 holdings

Natera Inc (3.33 %)

Incyte Corp (2.95 %)

Gilead Sciences Inc (2.81 %)

BetaShares Mrtn Currie Rl Inc Fund (Managed Fund) (100 %)

Top 3 industries

Health Care (100.00 %)

Other (10.24 %)

Top 3 countries

United States (97.17 %)

Switzerland (1.51 %)

United Kingdom of Great Britain and Northern Ireland (1.16 %)

Australia (67.74 %)

New Zealand (11.82 %)

United States (6.44 %)

Management fee

0.45 %

0.85 %


Key Summary

CURE

RINC

Issuer

Global X

BetaShares

Tracking index

S&P Biotechnology Select Industry

S&P ASX 200

Asset class

ETF

ETF

Management fee

0.45 %

0.85 %

Price

$51.33

$9.07

Size

$36.301 million

$54.769 million

10Y return

N/A

N/A

Annual distribution/ dividend yield (5Y)

4.24 %

4.14 %

Market

ASX

ASX

First listed date

12/11/2018

19/02/2018

Purchase fee

$6.50

$6.50


Community Stats

CURE

RINC

Popularity

Low

Low

Pearlers invested

83

1

Median incremental investment

$619.50

$1,094.28

Median investment frequency

Monthly

Monthly

Median total investment

$1,437.24

$172.33

Average age group

> 35

26 - 35


Pros and Cons

CURE

RINC

Pros

  • Higher exposure to US market

  • Lower management fee

  • Higher distribution yield

  • Higher exposure to AU market

  • Higher price growth

Cons

  • Lower exposure to AU market

  • Lower price growth

  • Lower exposure to US market

  • Higher management fee

  • Lower distribution yield

CURE

RINC

Lower exposure to AU market

Higher exposure to AU market

Higher exposure to US market

Lower exposure to US market

Lower management fee

Higher management fee

Lower price growth

Higher price growth

Higher distribution yield

Lower distribution yield

Home